Clik here to view.
Amarantus to Present at 9th Annual LD Micro Invitational Conference
New York, NY, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
View ArticleClik here to view.
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF...
New York, NY, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company...
View ArticleClik here to view.
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome...
NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company...
View ArticleClik here to view.
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to...
NEW YORK, NY, June 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company...
View ArticleClik here to view.
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to...
Amarantus is receiving Emerald Preferred Stock with a minimum value of $100M in 2022 Treatment candidates are for Alzheimer’s, ADHD, Parkinson’s, severe burns and vision loss Portfolio includes two...
View ArticleClik here to view.
Amarantus Provides Recapitalization Update to Shareholders
Pending license with Emerald provides opportunity to realize therapeutic portfolio value JV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trial Amarantus management...
View ArticleClik here to view.
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and...
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:...
View ArticleClik here to view.
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of...
· Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,”...
View ArticleClik here to view.
Amarantus to Present at 12th Annual LD Micro Main Event
NEW YORK, NY, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
View ArticleClik here to view.
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic...
Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02, 2020 (GLOBE...
View ArticleClik here to view.
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
Strong customer retention at both stores in Dallas, TX with growing online presence Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide...
View ArticleClik here to view.
Amarantus Releases Letter to Shareholders
New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
View ArticleClik here to view.
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material...
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
View Article